(UNICEF) and partner agencies supported injection safety by supplying developing countries with sterilizable glass syringes with detachable needles and portable steam sterilization kits, fuel, and extensive training for health workers to operate them. Gradually, middle-income countries started to imitate good practice in industrialized countries by switching to disposable plastic syringes with detachable needles. However, as during the 1990s it became clear that injection safety was still a problem in many countries in sub-Saharan Africa, UNICEF and partners decided to put additional measures into place to improve immunization practices, including guidelines, a joint statement, and an exclusive supply of AD syringes and safety boxes for contaminated sharps [1, [3] [4] [5] . The problematic reuse of disposable syringes and inadequately sterilized syringes by staff of the immunization services prompted industry to develop an AD syringe designed to lock automatically after a single injection, thus preventing reuse of the syringe.
The World Health Organization (WHO) and UNICEF called for an improvement in injection safety standards, including the use of AD syringes for administering vaccines and safety boxes to collect sharps after use. A safe injection can be defined as one that results in no harm to the recipient, the vaccinator, or the surrounding community. Proper equipment, such as AD syringes and safety boxes, is necessary [6] . These must be used efficiently and exclusively. Initially, the recommendation referred specifically to mass vaccination supplemental immunization activities (SIAs) [7] . In 1999, a joint statement by the WHO, UNICEF, the United Nations Population Fund, and the International Federation of the Red Cross and Crescent Societies was issued that urged countries to use AD syringes in all immunization activities [8] .
In 1992, one single type of 0.5-mL AD syringe was prequalified by the WHO for purchase through the United Nations system. The AD syringe was offered at a price of US $0.13 per unit to UNICEF, compared with approximately US $0.02 per disposable syringe. Countries started to introduce AD syringes while simultaneously phasing out older technology in the immunization program. Despite these efforts, change to improved injection safety technology was limited. By 1997, countries had purchased 11.3 million syringes through UNICEF, but many countries remained reluctant to purchase the AD syringes because of the price. By 2003, the price had decreased by half, and UNICEF made it a policy to ship only AD syringes for all 0.05-, 0.1-, and 0.5-mL syringes to be used in the immunization program. UNICEF's deliveries of AD syringes to the countries increased substantially from 2000 onward (see Figure 1) . At the same time, the use of sterilizable syringes was phased out; they remained in use in 31 countries in 2001 but only 5 in 2006 (China, Cuba, Haiti, Kiribati, and Micronesia). Meanwhile, China and Haiti stopped using sterilizable syringes for immunization in 2007.
From 2001 onward, the Measles Initiative (MI) started largescale, nationwide measles catch-up SIAs in sub-Saharan Africa (countries included in this analysis: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo (Brazzaville), (Kinshasa), Côte d'Ivoire, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, Togo, Uganda, Zambia, and Zimbabwe), typically targeting all children aged 9 months to 14 years. The MI is a partnership committed to decreasing measles deaths globally. Launched in 2001, the MI-led by the American Red Cross, the United Nations Foundation, the US Centers for Disease Control and Prevention (CDC), UNICEF, and the WHOprovides technical and financial support to governments and communities for vaccination SIAs and disease surveillance worldwide.
All measles SIAs funded by the MI were conducted using safe injection materials as the new gold standard in immunization to Figure 1 . Number of 0.5-mL auto-disable syringes shipped to sub-Saharan Africa by the United Nations Children's Fund, 2000-2008. improve injection safety: AD syringes, reconstitution syringes, and safety boxes, in compliance with the WHO/UNICEF measles strategic plan [9] .
The measles control strategy aims (1) to achieve a high rate of coverage of the first measles vaccine dose in infants; (2) to provide a second dose through routine immunization services in countries with high immunization coverage, and in countries with low immunization coverage through a catch-up SIA followed by a follow-up SIA every 3-4 years, the latter typically targeting all children between 9 month of age and 4-5 years of age; (3) to improve laboratory-backed measles surveillance; and (4) to enhance case management, including vitamin A supplementation. The strategy was adopted after the tremendous success in reducing measles-related deaths in the Americas and similar success in 7 countries in southern Africa between 1996 and 2000 (Botswana, Lesotho, Malawi, Namibia, South Africa, Swaziland, and Zimbabwe) [9, 10] .
Since 2002, the Global Alliance for Vaccines and Immunisation (GAVI) has provided an opportunity for the poorest countries to receive injection safety support (INS). For each country, this included in-kind donation of AD syringes, reconstitution syringes, and safety boxes in quantities sufficient to vaccinate all women and infants aged ,1 year who are targeted in national immunization schedules. Some countries received support in cash [11] . Funding support was provided during a 3-year period to each country. This paper analyzes the catalytic effect that measles catch-up SIAs and the GAVI INS funding had on the introduction and scale-up of the use of safe injection materials in sub-Saharan Africa.
METHODS
This paper compares the timing of the measles catch-up SIAs supported by the MI, the period of GAVI INS funding, and the timing of nationwide introduction of AD syringes in the country, as reported by Ministries of Health in the Joint Reporting Form (JRF) for immunization submitted annually to the WHO and UNICEF. For the analysis, we used JRF data, WHO measles SIA data, UNICEF supply data, and publicly available GAVI data. The paper focuses on 39 countries in sub-Saharan Africa that conducted measles catch-up SIAs between 2001 and 2008 (see Tables 1 and 2 ). We chose this period because the MI started in 2001 and the latest available JRF data at the time our data analysis was performed were for 2008. JRF data were verified with the UNICEF AD syringe shipment data to countries: we assumed that, if a country's AD syringe supply was greater than the number of children to be vaccinated with the complete childhood immunization series and no mass SIA was conducted during that year, the country had implemented the use of AD syringes in all districts. The timing and type of GAVI INS funding, provided between 2002 and 2008, was analyzed on the basis of data and reports available on the GAVI website [12] . The timing and the results of the SIAs were collected from reports from the countries and compared with the WHO database of measles activities [13, 14] . Countries that started catchup SIAs before 2001, Botswana (1997), Lesotho (1999) , Malawi (1998), Namibia (1997), South Africa (1996), Swaziland (1998), and Zimbabwe (1998), were excluded from this analysis, because countries did not use AD syringes at the time of those SIAs [10] . The higher standard of injection safety was set and adopted by the MI after the 1999 joint statement on injection safety in immunization [8] .
The measles follow-up SIAs were excluded from the analysis, because the AD syringes had already been introduced during the catch-up SIA. Typically, follow-up SIAs are conducted only after the catch-up SIAs are finished in each country and these SIAs continue to use AD syringes only.
RESULTS

Measles Catch-up SIA as Catalyst
Measles catch-up SIAs were planned and implemented by the national Ministries of Health with technical assistance from the WHO, UNICEF, and the CDC. The SIAs were conducted according to the global measles strategic plan [9] . Funding became available through the CDC, the United Nations Foundation, the American Red Cross, and other partners. GAVI has provided about 25% of the MI budget through 2008.
A total of 263 million children in sub-Saharan Africa were vaccinated using AD syringes in the 39 countries during catchup SIAs between 2001 and 2008. Catch-up SIAs typically targeted all children in each country between 9 months and 14 years of age during a 2-3 week period.
Eight countries began conducting catch-up measles SIAs in 2001 (Benin, Burkina Faso, Cameroon, Ghana, Mali, Togo, Uganda, and Tanzania). Tables 1  and 2 ).
As part of the SIA preparations in all 39 countries, a large part of the Ministry of Health workers cadre and all vaccinators were trained in injection safety, ie, vaccine storage, reconstitution, mixing, and injection, use of the AD syringe, disposal of syringes in safety boxes, waste management, and surveillance for and management of adverse events following immunization. Of 39 countries, 16 (including Nigeria) started using the AD syringe for routine immunization in all districts after introducing it in measles catch-up SIAs. In addition to the theoretical training that was received, measles SIAs provided a critical opportunity for hands-on training for all vaccinators in using the new technology. Tables 1 and 2 GAVI provided INS in kind by procuring safe injection materials (AD syringes, reconstitution syringes, and safety boxes) for routine immunization services to 29 of the 39 countries in sub-Saharan Africa. In addition, GAVI provided INS in the form of cash support to 6 African countries. All 6 countries had already introduced AD syringes prior to the start of the GAVI support. Rwanda and Somalia used the funds for international procurement of AD syringes, reconstitution syringes, and safety boxes, whereas Djibouti, Ghana, Mauritania, and Tanzania used the funds for construction and/or maintenance of incinerators. After the period of GAVI support, all supported African countries found domestic or donor funding to continue the procurement of safe injection materials and continued using AD syringes for their routine immunization programs [11] . 
GAVI Injection Safety Support
GAVI INS funding was provided to GAVI-eligible countries upon their request. From 2002 onward, 46 countries worldwide received support consisting of safe injection commodities for their routine vaccination program during 3 consecutive years. Of the 39 countries evaluated in this paper, 35 received GAVI INS (see
Reduction in Use of Sterilizable Syringes
During the 1990s, sterilizable syringes were still used regularly in the immunization programs. With the introduction of AD syringes in sub-Saharan Africa, the use of sterilizable syringes for routine immunization has rapidly decreased. In 2000, 22 subSaharan African countries reported the use of sterilizable syringes for immunizations. According to the JRF, none of the countries used sterilizable syringes in 2004 or after.
Countries That Conducted Measles SIAs Prior to 2000
Although this was not the primary purpose of our analysis, we note that all 7 countries that started catch-up SIAs before 2001 (Botswana, Lesotho, Malawi, Namibia, South Africa, Swaziland, and Zimbabwe) did not use AD syringes for their immunization activities at that time. Three of these countries (Malawi, Lesotho, and Zimbabwe) were eligible for GAVI INS. As of 2008, 6 of these 7 countries had introduced AD syringes in their immunization programs; only South Africa had not (see Tables 1 and 3 ).
DISCUSSION
The critical step for improving safe injection practices in immunization programs to protect the beneficiaries of the vaccines is the universal use of AD syringes, which are designed to lock automatically after a single injection. In addition, safety boxes are needed for the collection of used syringes, and procedures need to be in place for disposal of the waste.
Since the 1990s, UNICEF and the WHO have encouraged the improvement of injection safety standards for immunizations through both bundling vaccines with appropriate amounts of supporting equipment and supplying AD syringes for injections. The success of introducing these syringes in immunization programs in the developing world was due to increased awareness regarding the risks of reusable syringes, large-scale mass SIAs, and support from GAVI.
Since The MI partners have ensured sufficient provision of AD syringes, reconstitution syringes, and safety boxes to vaccinate typically all children from 9 months to 14 years of age during each measles catch-up SIA, by funding and delivering safety devices and monitoring their use at the operational level. In 16 (41%) of 39 countries that conducted measles SIAs in subSaharan Africa, the measles catch-up SIA catalyzed nationwide introduction of AD syringes, reconstitution syringes, and safety boxes, reaching .173 million children (see Tables 1 and 2 ). GAVI INS funding was associated with the introduction of AD syringes and safe injection materials in 14 (36%) of 39 countries, as AD syringe availability in all districts was reported only in the same year or after the GAVI INS had started. The GAVI INS established the new technology in the routine program and ensured that financing for the safe injection material was available for 3 years. By the time GAVI support ended, countries continued to use AD syringes in their immunization programs. Domestic funding, donor funding, or a combination of these were used to purchase AD syringes.
AD syringes are now the standard for delivery of immunization in sub-Saharan Africa. The use of sterilizable syringes for immunization ended in 2004; hence, it is assumed that the unnecessary risk for health care-associated infections due to hepatitis B, hepatitis C, HIV, and other bloodborne pathogens is effectively reduced within the immunization programs.
One gap in the current strategy to prevent syringe reuse remains. The continued use of standard disposable syringeswhich do not have this disabling mechanism-for the reconstitution of lyophilized vaccines continues to put immunization programs at risk of contamination. The problem of this gap is important, in light of the fact that, worldwide, reconstitution was required by nearly 450 million doses of UNI-CEF vaccine in 2007 [15] . Recently, the attention of safe injection advocates has moved beyond the scope of the syringes used to administer injections to include those used to reconstitute vials of vaccine. The use of nonreusable syringes for reconstitution in conjunction with providing AD syringes for injections could potentially eliminate the possibility of syringe reuse during immunization sessions and would provide a more comprehensive and consistent injection safety policy, closing the safety gap in current immunization programs.
The measles strategy has been one of the most successful public health strategies in reducing child mortality. In the WHO [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] African region (AFRO), measles mortality decreased 92% from an estimated 371,000 (95% confidence interval, 270,000-483,000) in 2000 to an estimated 28,000 (95% confidence interval, 19,000-40,000) in 2008, as a result of the implementation of the comprehensive measles control strategy that has used safe injection practices as a core principle [15, 16] .
There are a few limitations to this report. First, the JRF contains self-reported data from Ministries of Health to UNI-CEF and the WHO. Second, data from some countries that did not purchase AD syringes through UNICEF but directly from suppliers will not have been included in our analysis, leading to a possible underreporting of the number of AD syringes for the reviewed time period. Third, although we are unsure whether all reported AD syringes were actually used for the immunization program, we assume that, because 0.5-mL syringes can be used only in immunization programs and have no further value to other programs, it is unlikely that the syringes would have been sold or used elsewhere.
In summary, the measles mortality reduction program and GAVI support complemented one another in improving injection safety-the measles program by training the health care workers prior to the measles catch-up SIAs and by procuring safe injection equipment during SIAs and GAVI through financial support for including safe injection equipment in the routine immunization service delivery. Together, the programs are associated with the introduction of AD syringes in 19 (49%) of the 39 countries evaluated. All countries evaluated continued with AD syringes for SIAs and routine immunization even after measles catch-up SIAs and the GAVI funding ended.
